IN2014DN11272A - - Google Patents

Info

Publication number
IN2014DN11272A
IN2014DN11272A IN11272DEN2014A IN2014DN11272A IN 2014DN11272 A IN2014DN11272 A IN 2014DN11272A IN 11272DEN2014 A IN11272DEN2014 A IN 11272DEN2014A IN 2014DN11272 A IN2014DN11272 A IN 2014DN11272A
Authority
IN
India
Prior art keywords
recombinant
protein
mammalian cells
present
fge
Prior art date
Application number
Inventor
Chun Zhang
Ferenc Boldog
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of IN2014DN11272A publication Critical patent/IN2014DN11272A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides among other things methods and compositions for large scale production of recombinant I2S protein using suspension culture of mammalian cells in serum free medium. In particular the present invention uses mammalian cells co express a recombinant I2S protein and a formylglycine generating enzyme (FGE).
IN11272DEN2014 2012-06-29 2013-06-28 IN2014DN11272A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666712P 2012-06-29 2012-06-29
PCT/US2013/048601 WO2014005036A1 (en) 2012-06-29 2013-06-28 Method of producing recombinant iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
IN2014DN11272A true IN2014DN11272A (en) 2015-10-09

Family

ID=49778402

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11272DEN2014 IN2014DN11272A (en) 2012-06-29 2013-06-28

Country Status (21)

Country Link
US (1) US20140004097A1 (en)
EP (1) EP2867367A4 (en)
JP (1) JP2015523074A (en)
KR (1) KR20150037908A (en)
CN (1) CN104583414A (en)
AU (1) AU2013282417A1 (en)
BR (1) BR112014032544A2 (en)
CA (1) CA2877492A1 (en)
CL (1) CL2014003569A1 (en)
CO (1) CO7240395A2 (en)
CR (1) CR20140587A (en)
DO (1) DOP2014000297A (en)
EA (1) EA201492185A1 (en)
HK (2) HK1209790A1 (en)
IL (1) IL236324A0 (en)
IN (1) IN2014DN11272A (en)
MX (1) MX2015000188A (en)
PE (1) PE20150603A1 (en)
PH (1) PH12014502870A1 (en)
SG (1) SG11201408755TA (en)
WO (1) WO2014005036A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (en) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 Purification of iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN104662150B (en) * 2012-07-31 2018-07-10 比奥阿赛斯技术有限公司 The lysosomal storage disease albumen and its application method of dephosphorylation
JP6586412B2 (en) 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド p97 fragment and use thereof
ES2762672T3 (en) * 2014-02-19 2020-05-25 Bioasis Technologies Inc P97-IDS fusion proteins
JP6785777B2 (en) 2015-02-05 2020-11-18 アール．ピー． シェーラー テクノロジーズ エルエルシー Activated formylglycine-producing enzyme and its production method and usage
KR20180063179A (en) * 2015-10-07 2018-06-11 조엘 후이젠가 Recovery of biological pathways for defense and recovery of aging due to human aging
ES2908470T3 (en) 2015-11-09 2022-04-29 Scherer Technologies Llc R P Anti-CD22-maytansine antibody conjugates and methods of using the same
CN109689191B (en) * 2016-07-25 2021-11-19 瑞普利金公司 Alternate tangential flow rapid harvest
MA50746A (en) 2017-10-02 2020-08-12 Denali Therapeutics Inc FUSION PROTEINS INCLUDING SUBSTITUTIVE ENZYMOTHERAPY ENZYMES

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008934A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
DE60032349T2 (en) * 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco CELL FARMING FOR GLYCOPROTEINS
US6890736B1 (en) * 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
SI2325302T1 (en) * 2003-02-11 2016-05-31 Shire Human Genetic Therapies, Inc. Cells that coexpress a sulfatase and a C-formylglycine generating enzyme and methods and uses thereof
US20050019914A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
EP2267024B1 (en) * 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
US7888101B2 (en) * 2005-12-08 2011-02-15 Amgen Inc. Host cells comprising alpha 1,2 mannosidase and culture methods thereof
MX2010007846A (en) * 2008-01-18 2010-10-05 Biomarin Pharm Inc MANUFACTURE OF HUMAN LISOSOMAL SULFATASE ENZYMES HIGHLY PHOSPHORILED, ACTIVE AND USES OF THE SAME.
ES2725200T3 (en) * 2009-10-09 2019-09-20 Armagen Inc Methods and compositions to increase the activity of iduronate 2-sulfatase in the CNS
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
PL2593131T3 (en) 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of iduronate-2-sulfatase
KR101158673B1 (en) * 2011-06-24 2012-07-03 주식회사 지씨바이오 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase

Also Published As

Publication number Publication date
EP2867367A1 (en) 2015-05-06
PH12014502870A1 (en) 2015-02-23
CN104583414A (en) 2015-04-29
CA2877492A1 (en) 2014-01-03
EA201492185A1 (en) 2015-10-30
AU2013282417A1 (en) 2015-01-29
BR112014032544A2 (en) 2017-08-01
WO2014005036A1 (en) 2014-01-03
MX2015000188A (en) 2015-04-08
DOP2014000297A (en) 2015-04-15
HK1209458A1 (en) 2016-04-01
JP2015523074A (en) 2015-08-13
CL2014003569A1 (en) 2015-04-17
HK1209790A1 (en) 2016-04-08
IL236324A0 (en) 2015-02-26
CR20140587A (en) 2015-04-06
KR20150037908A (en) 2015-04-08
US20140004097A1 (en) 2014-01-02
CO7240395A2 (en) 2015-04-17
EP2867367A4 (en) 2016-02-24
PE20150603A1 (en) 2015-05-27
SG11201408755TA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
IN2014DN11272A (en)
MX355650B (en) Production of proteins in glutamine-free cell culture media.
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
MX2021008142A (en) Methods for harvesting mammalian cell cultures.
PE20150957A1 (en) CELLS TO PRODUCE RECOMBINANT IDURONATE-2-SULFATASE
MX344970B (en) Cell culture medium for adamts protein expression.
MX2019003427A (en) Cell culture compositions and methods for polypeptide production.
MX338560B (en) Fusion enzymes having n-acetylglucosaminyltransferase activity.
IN2014DN10996A (en)
EP3763810A3 (en) T cell modifying compounds and uses thereof
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
PH12014501019A1 (en) Kit comprising serum replacement and labile factors
IN2014CN02963A (en)
EA201170025A1 (en) METHODS OF INCREASING THE VIABILITY AND PRODUCTION OF CULTURE OF CELLS
CA2830600C (en) Compositions and methods for enhancing the pluripotency of stem cells
AU2018276376A1 (en) Cell culture methods
MX2010005079A (en) Methods of measuring cell viability without using control cells.
MX2015010887A (en) Formulations and methods for increased recombinant protein production.
WO2015117033A3 (en) Methods of increasing protein production in mammalian cells